OncoMatch/Clinical Trials/NCT06649058
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
Is NCT06649058 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for brain metastases.
To learn if consolidative stereotactic radiosurgery (cSRS) can help to control central nervous system (CNS) disease in patients who have brain metastases and have a partial response or stable brain metastases after systemic therapy. To learn if using SRS to treat all brain metastases that do not respond to systemic therapy versus treating only metastases that are getting worse can help to control CNS disease in patients whose disease gets worse after systemic therapy.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Excluded: EGFR targetable oncogenic driver mutation
Non-small cell lung cancer histology with targetable oncogenic driver mutation with planned initiation of highly CNS active targeted therapy (eg osimertinib, brigatinib, alectinib, or lorlatinib)
Excluded: ALK targetable oncogenic driver mutation
Non-small cell lung cancer histology with targetable oncogenic driver mutation with planned initiation of highly CNS active targeted therapy (eg osimertinib, brigatinib, alectinib, or lorlatinib)
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: whole brain radiation therapy
Subjects previously treated with WBRT
Cannot have received: systemic therapy (SST) agents
Exception: if prior disease progression on one or more of the agents comprising SST
Prior disease progression on one or more of the agents comprising SST
Cannot have received: systemic therapy (SST) agents
Exception: if exposure to one or more agents comprising SST within the last 30 days
Exposure to one or more agents comprising SST within the last 30 days
Cannot have received: systemic therapy (SST) agents
Exception: if prior unacceptable toxicity during treatment with one or more agents comprising SST
Prior unacceptable toxicity during treatment with one or more agents comprising SST
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify